Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”…
Merus Announces FDA Approval of BIZENGRI (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ NonSmall Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
BIZENGRI® is the first and only therapy approved by the FDA specifically…